Osteoprotegerin: a novel secreted protein involved in the regulation of bone density
- PMID: 9108485
- DOI: 10.1016/s0092-8674(00)80209-3
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density
Abstract
A novel secreted glycoprotein that regulates bone resorption has been identified. The protein, termed Osteoprotegerin (OPG), is a novel member of the TNF receptor superfamily. In vivo, hepatic expression of OPG in transgenic mice results in a profound yet nonlethal osteopetrosis, coincident with a decrease in later stages of osteoclast differentiation. These same effects are observed upon administration of recombinant OPG into normal mice. In vitro, osteoclast differentiation from precursor cells is blocked in a dose-dependent manner by recombinant OPG. Furthermore, OPG blocks ovariectomy-associated bone loss in rats. These data show that OPG can act as a soluble factor in the regulation of bone mass and imply a utility for OPG in the treatment of osteoporosis associated with increased osteoclast activity.
Comment in
-
Bone morphogenesis and modeling: soluble signals sculpt osteosomes in the solid state.Cell. 1997 Apr 18;89(2):159-61. doi: 10.1016/s0092-8674(00)80193-2. Cell. 1997. PMID: 9108469 Review. No abstract available.
Similar articles
-
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.J Exp Med. 2000 Aug 21;192(4):463-74. doi: 10.1084/jem.192.4.463. J Exp Med. 2000. PMID: 10952716 Free PMC article.
-
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.J Bone Miner Res. 2000 Jan;15(1):2-12. doi: 10.1359/jbmr.2000.15.1.2. J Bone Miner Res. 2000. PMID: 10646108 Review.
-
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3540-5. doi: 10.1073/pnas.96.7.3540. Proc Natl Acad Sci U S A. 1999. PMID: 10097072 Free PMC article.
-
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.Cell. 1998 Apr 17;93(2):165-76. doi: 10.1016/s0092-8674(00)81569-x. Cell. 1998. PMID: 9568710
-
Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.Cancer. 2001 Aug 1;92(3):460-70. doi: 10.1002/1097-0142(20010801)92:3<460::aid-cncr1344>3.0.co;2-d. Cancer. 2001. PMID: 11505389 Review.
Cited by
-
Skeletal and extraskeletal actions of denosumab.Endocrine. 2012 Aug;42(1):52-62. doi: 10.1007/s12020-012-9696-x. Epub 2012 May 13. Endocrine. 2012. PMID: 22581255 Review.
-
Denosumab improves bone mineral density and microarchitecture and reduces bone pain in women with osteoporosis with and without glucocorticoid treatment.Biotechnol Biotechnol Equip. 2014 Nov 2;28(6):1127-1137. doi: 10.1080/13102818.2014.967827. Epub 2014 Oct 17. Biotechnol Biotechnol Equip. 2014. PMID: 26019600 Free PMC article.
-
The role and mechanism of protein post‑translational modification in vascular calcification (Review).Exp Ther Med. 2024 Sep 6;28(5):419. doi: 10.3892/etm.2024.12708. eCollection 2024 Nov. Exp Ther Med. 2024. PMID: 39301258 Free PMC article. Review.
-
Death receptor-ligand systems in cancer, cell death, and inflammation.Cold Spring Harb Perspect Biol. 2013 May 1;5(5):a008698. doi: 10.1101/cshperspect.a008698. Cold Spring Harb Perspect Biol. 2013. PMID: 23637280 Free PMC article. Review.
-
Osteoprotegerin inhibits calcification of vascular smooth muscle cell via down regulation of the Notch1-RBP-Jκ/Msx2 signaling pathway.PLoS One. 2013 Jul 9;8(7):e68987. doi: 10.1371/journal.pone.0068987. Print 2013. PLoS One. 2013. PMID: 23874840 Free PMC article.
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases